Common genetic differences may help predict how well patients respond to GLP-1–based weight-loss drugs and their risk of side effects, according to a large population study.
In a study published in Nature, researchers analyzed data from nearly 28,000 people using GLP-1 receptor agonists, including semaglutide and tirzepatide, and identified genetic variants that influence both weight loss and treatment tolerability. The findings suggest that variation in the same biological pathways targeted by these drugs can partly explain why some patients respond better than others.
A key result was the identification of a variant in the GLP1 receptor gene that was associated with greater weight loss. Each copy of this variant was linked to an additional reduction of about 0.76 kg, highlighting a measurable – though modest – effect on treatment outcomes.
For clinicians, the implication is that response to GLP-1 therapies is not solely determined by adherence or clinical characteristics. While factors such as sex, age, treatment duration, and drug choice explained much of the variation in weight loss, genetics added another layer of predictive value. Together, these factors accounted for roughly one-quarter of the variability in treatment response.
The study also identified genetic links to common side effects. Variants near the GLP1 receptor gene were associated with nausea and vomiting, and a separate variant in the GIP receptor gene increased the risk of vomiting specifically in patients taking tirzepatide.
Notably, the data suggest a relationship between efficacy and tolerability. Patients with genetic variants associated with greater weight loss were also more likely to experience gastrointestinal side effects, indicating a shared biological mechanism.
From a clinical perspective, these findings support the potential for stratified prescribing. Predictive models combining genetic and clinical data were able to distinguish patients more likely to achieve greater weight loss or experience adverse effects, although genetic factors alone contributed only modestly to prediction accuracy.
The results point toward a future in which baseline patient characteristics – including genetic information – could guide drug selection, dosing strategies, and counseling about expected outcomes. For now, the study provides early evidence that precision medicine approaches may help optimize the use of GLP-1 therapies in routine care.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
